标题：Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?

作者：Pérez-Soler R

网址:

求助者：丁丁ding

• 求助时间：2015/6/26 22:45:11
• 求助状态：AB图书馆客服已找到全文，详情咨询在线客服qq 1257749646
• 文献摘要：

Rash is a class effect of HER1/epidermal growth factor receptor (EGFR)-targeted agents, and has occurred with high frequency and in a dose-dependent manner in clinical trials of these agents in cancer patients. Analysis of phase II trials of erlotinib (Tarceva) in non-small-cell lung cancer, head and neck cancer, and ovarian cancer shows a significant association between rash severity and objective tumor response. Rash severity was highly significantly associated with survival in patients with non-small-cell lung cancer receiving erlotinib; median survival in patients with no rash was 46.5 days, compared with 257 days in those with grade 1 rash (P < .0001) and 597 days in those with grade 2/3 rash (P < .0001). Similarly, for the combined non-small-cell lung cancer, head and neck cancer, and ovarian cancer studies, median survival in patients with no rash was 103 days, compared with 191 days in those with grade 1 rash (P = .0001) and 266 days in those with grade 2/3/4 rash (P = .0001). Similar findings have been made with cetuximab (Erbitux) and in some settings with gefitinib (Iressa). The strong association of rash severity with response/survival suggests that rash may serve as a marker of response to erlotinib treatment and may be used to guide treatment to obtain optimal response. Dosing erlotinib at the maximum tolerated dose, which is associated with more frequent and more severe rash, may improve response rates and survival durations. Further study of the potentially important association between rash and outcome of treatment with EGFR-targeted agents is needed.

文献《Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?》已经找到全文，详情请咨询在线客服 qq 1257749646。
如果您还有其他需要寻找全文的文献，请点击文献求助提交

说明：文献求助是指AB图书馆根据读者的需求，为读者查找论文资料的服务。如果您搜索到相关资料，但不能获取全文，此时便可将有关信息提交求助，由值班客服为您寻找所需文献的全文。提供的文献均来自网络共享资源，不涉及版权交易；如侵犯了您的权利，请告知在线客服，立马删除。文件格式以PDF格式为主。